Hong Kong stock abnormal | CRO concept stocks rebounded in the morning, overseas investment and financing gradually recovered. The pharmaceutical subdivision field and emerging businesses are expected to develop rapidly.

Concept stocks of CRO rebounded in early trading. As of the time of writing, Genscript Bio (01548) rose by 4.39% to HK$10.94; Tigermed (03347) rose by 4.47% to HK$33.85; Frontage (01521) rose by 2.75% to HK$1.12; Joinn Laboratories (06127) rose by 2.49% to HK$9.47; Wuxi Bio (02269) rose by 1.68% to HK$14.54.

Zhitong FinanceNov 26 22:02 ET

Southwest Securities: CXO industry revenues are recovering season by season, but the demand for preclinical services still needs to be restored.

From a short-term perspective, commercial orders continue to be digested, putting pressure on the apparent performance of CDMO; overseas mature CXO clinical pipelines are steadily advancing, and the preclinical demand still needs to be restored.

Zhitong FinanceNov 26 01:00 ET

Trending Industry Today: WUXI APPTEC Leads Losses In Biotechnology Stocks

Moomoo NewsNov 22 02:50 ET

Trending Industry Today: PHARMARON Leads Losses In CRO Stocks

Moomoo NewsNov 22 02:40 ET

Wuxi Bio (02269): Miao Jingwen has been appointed as a non-executive director.

Wuxi Bio (02269) announced that effective from November 20, 2024: Dr. Wu Yibing has resigned from his position as...

Zhitong FinanceNov 20 06:26 ET

Contract research organizations concept rises, Joinn Laboratories (06127) rises by 5.11%, institutions say CXO sector is expected to benefit from the recovery of overseas research and development demand.

Jinwu Financial News | The concept of contract research organizations has risen across the board, with joinn laboratories (06127) up 5.11%, tigermed (03347) up 4.33%, frontage (01521) up 2%, pharmaron (03759) up 1.84%, and wuxi bio (02269) up 0.79%. Zhongtai reported that the bank believes that as the medical insurance fund prepayment system continues to deepen and improve, and the supporting DRG/DIP system is continuously implemented in various provinces and cities, the long-term "triangle debt" relationship among hospitals, pharmaceutical companies, and medical insurance persists, and the "zero markup policy on pharmaceuticals" compresses hospital profitability.

Golden Guard Financial NewsNov 19 21:46 ET